Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
Recruiting now
Conditions studied: CD30-Positive Peripheral T-Cell Lymphoma
In brief
The goal of this observational study is to evaluate how well brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (CHP) works and how safe it is when used as first-line treatment in adults with CD30-positive peripheral T-cell lymphoma in Spain during routine clinical care. The main questions this study aims to answer are: * How long do participants live without their lymphoma getting worse after starting treatment? * How well does this treatment reduce or eliminate the lymphoma? * How long do participants live after receiving this treatment? * What side effects do participants experience, including nerve problems and low white blood cell counts? Participants have already received brentuximab vedotin plus CHP as part of their usual medical care. Researchers will collect information from existing medical records to better understand treatment outcomes and safety in real-world clinical practice across multiple centers in Spain.
Key facts
- Study ID
- NCT07624838
- Run by
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- People needed
- 100
- Starts
- 2026-02-15
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2026-06-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of CD30-positive peripheral T-cell lymphoma, including anaplastic large cell lymphoma (ALK-positive, ALK-negative, breast implant-associated), peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma.
- Patients 18 years of age or older at the time of treatment with BV-CHP.
- Patients treated with brentuximab vedotin plus CHP as first-line therapy between January 2019 and September 2024
You may not qualify if…
- Patients who have received prior treatment for their lymphoma
- Patients who have received the combination as part of a clinical trial.
Where it is running
- Hospital Universitario A Coruña — A Coruña, A Coruña, Spain (enrolling)
- Hospital Universitari Son Llàtzer — Palma de Mallorca, Balearic Islands, Spain (enrolling)
- Hospital Universitari Son Espases — Palma de Mallorca, Balearic Islands, Spain (enrolling)
- ICO Hospital Germans Trias i Pujol — Badalona, Barcelona, Spain (enrolling)
- Hospital del Mar — Barcelona, Barcelona, Spain (enrolling)
- Hospital Universitari Vall d'Hebron — Barcelona, Barcelona, Spain (enrolling)
- Hospital Clínic de Barcelona — Barcelona, Barcelona, Spain (enrolling)
- Hospital de la Santa Creu i Sant Pau — Barcelona, Barcelona, Spain (enrolling)
- ICO Hospital Duran i Reynals — L'Hospitalet de Llobregat, Barcelona, Spain (enrolling)
- Hospital Moisès Broggi — Sant Joan Despí, Barcelona, Spain (enrolling)
- Hospital Universitario Marqués de Valdecilla — Santander, Cantabria, Spain (enrolling)
- Hospital Universitario de Jerez — Jerez de la Frontera, Cádiz, Spain (enrolling)
- Hospital Universitario Donostia — San Sebastián, Gipuzkoa, Spain (enrolling)
- ICO Girona - Hospital Dr. Josep Trueta — Girona, Girona, Spain (enrolling)
- Hospital Universitario Juan Ramón Jiménez — Huelva, Huelva, Spain (enrolling)
- Hospital Universitario Doctor Negrín — Las Palmas de Gran Canaria, Las Palmas, Spain (enrolling)
- Hospital Universitario Príncipe de Asturias — Alcalá de Henares, Madrid, Spain (enrolling)
- Hospital del Sureste — Arganda, Madrid, Spain (enrolling)
- Hospital Universitario Severo Ochoa — Leganés, Madrid, Spain (enrolling)
- Hospital Universitario de La Princesa — Madrid, Madrid, Spain (enrolling)
- Hospital Universitario Gregorio Marañón — Madrid, Madrid, Spain (enrolling)
- Hospital Universitario Ramón y Cajal — Madrid, Madrid, Spain (enrolling)
- Hospital Universitario 12 de Octubre — Madrid, Madrid, Spain (enrolling)
- Hospital Universitario Rey Juan Carlos — Móstoles, Madrid, Spain (enrolling)
- Hospital General Universitario Santa Lucía — Cartagena, Murcia, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.